Clinical Trials Logo

Clinical Trial Summary

This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.


Clinical Trial Description

Approximately 250 subjects are planned to be included in the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05089357
Study type Observational
Source Galderma R&D
Contact
Status Completed
Phase
Start date November 11, 2021
Completion date December 24, 2023

See also
  Status Clinical Trial Phase
Completed NCT04096326 - AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase 2
Completed NCT02961673 - The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines Phase 1/Phase 2
Completed NCT01271452 - Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines Phase 4
Completed NCT05013424 - A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Phase 2
Completed NCT01189760 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT05100199 - A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Phase 2
Completed NCT03721016 - MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) Phase 3
Completed NCT04157686 - MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) Phase 3
Completed NCT02353897 - Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
Completed NCT03732833 - MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines Phase 3
Completed NCT06212960 - Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines Phase 1
Completed NCT00408785 - A Study Of BOTOX For The Treatment Of Glabellar Lines Phase 3
Completed NCT05380154 - Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. Phase 3
Completed NCT01224015 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT05248880 - A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines Phase 3
Completed NCT05248867 - A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines Phase 3
Completed NCT03216408 - Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines Phase 3
Recruiting NCT06308198 - A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines Phase 3
Completed NCT05298449 - Phase 2 of HU-045 in Glabellar Lines Phase 2
Not yet recruiting NCT06246552 - Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines Phase 2